CA3064550A1 - Compositions et methodes de traitement de tauopathies - Google Patents
Compositions et methodes de traitement de tauopathies Download PDFInfo
- Publication number
- CA3064550A1 CA3064550A1 CA3064550A CA3064550A CA3064550A1 CA 3064550 A1 CA3064550 A1 CA 3064550A1 CA 3064550 A CA3064550 A CA 3064550A CA 3064550 A CA3064550 A CA 3064550A CA 3064550 A1 CA3064550 A1 CA 3064550A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- disease
- human tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000034799 Tauopathies Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims description 53
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims abstract description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 102000013498 tau Proteins Human genes 0.000 claims description 207
- 108010026424 tau Proteins Proteins 0.000 claims description 207
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 33
- 206010012289 Dementia Diseases 0.000 claims description 20
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 12
- 108091000054 Prion Proteins 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 208000017004 dementia pugilistica Diseases 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 10
- 229960003330 pentetic acid Drugs 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 9
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 9
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 9
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 9
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 9
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 9
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 9
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 9
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 8
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 7
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 230000009529 traumatic brain injury Effects 0.000 claims description 7
- 206010059245 Angiopathy Diseases 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 6
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 6
- 206010010254 Concussion Diseases 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 6
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims description 6
- 201000010374 Down Syndrome Diseases 0.000 claims description 6
- 208000032274 Encephalopathy Diseases 0.000 claims description 6
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 6
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims description 6
- 206010018341 Gliosis Diseases 0.000 claims description 6
- 208000026072 Motor neurone disease Diseases 0.000 claims description 6
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 6
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 6
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 6
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 6
- 206010044688 Trisomy 21 Diseases 0.000 claims description 6
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 6
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 230000007387 gliosis Effects 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 201000008319 inclusion body myositis Diseases 0.000 claims description 6
- 208000005264 motor neuron disease Diseases 0.000 claims description 6
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 230000002739 subcortical effect Effects 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000029797 Prion Human genes 0.000 claims 4
- 238000009472 formulation Methods 0.000 abstract description 42
- 150000001413 amino acids Chemical class 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 28
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 27
- 230000009467 reduction Effects 0.000 description 23
- 230000001629 suppression Effects 0.000 description 23
- 210000003722 extracellular fluid Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 230000006240 deamidation Effects 0.000 description 11
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 230000001174 ascending effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000012008 microflow imaging Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102100034452 Alternative prion protein Human genes 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000033444 hydroxylation Effects 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000012510 peptide mapping method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001508 asparagines Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102100027867 FH2 domain-containing protein 1 Human genes 0.000 description 1
- 101001060553 Homo sapiens FH2 domain-containing protein 1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des schémas posologiques et des formulations d'anticorps anti-tau humains. Ces formulations et schémas posologiques trouvent une utilisation dans le traitement de tauopathies telles que la paralysie supranucléaire progressive et la maladie d'Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/037991 WO2018231254A1 (fr) | 2017-06-16 | 2017-06-16 | Compositions et méthodes de traitement de tauopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3064550A1 true CA3064550A1 (fr) | 2018-12-20 |
Family
ID=59388133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3064550A Pending CA3064550A1 (fr) | 2017-06-16 | 2017-06-16 | Compositions et methodes de traitement de tauopathies |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3638694A1 (fr) |
JP (2) | JP2020529394A (fr) |
KR (1) | KR20200018502A (fr) |
CN (1) | CN110770253A (fr) |
AU (1) | AU2017418317A1 (fr) |
BR (1) | BR112019026298A2 (fr) |
CA (1) | CA3064550A1 (fr) |
EA (1) | EA202090063A1 (fr) |
IL (1) | IL271256A (fr) |
MX (1) | MX2019015071A (fr) |
WO (1) | WO2018231254A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
EP3452508A1 (fr) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Anticorps reconnaissant tau |
CN109415432B (zh) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | Tau免疫疗法 |
MX2019009817A (es) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
KR20200030029A (ko) | 2017-05-02 | 2020-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
EP4379054A1 (fr) | 2021-07-27 | 2024-06-05 | Stand Therapeutics Co., Ltd. | Marqueur peptidique et acide nucléique codant pour celui-ci |
KR20230172262A (ko) | 2022-06-15 | 2023-12-22 | 재단법인대구경북과학기술원 | Ptk2 억제제를 유효성분으로 포함하는 타우병증의 예방 또는 치료용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
CN102159204B (zh) * | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
ES2686550T3 (es) * | 2010-10-11 | 2018-10-18 | Biogen International Neuroscience Gmbh | Anticuerpos anti-tau humanos |
JP5941770B2 (ja) | 2012-06-28 | 2016-06-29 | 株式会社ミマキエンジニアリング | インクジェット記録装置、液体供給装置および記録ヘッドのクリーニング方法 |
KR102076384B1 (ko) * | 2012-08-16 | 2020-02-11 | 아이피어리언 인코포레이티드 | 타우병증을 치료하는 방법 |
EP3007726B1 (fr) * | 2013-06-10 | 2020-04-08 | Ipierian, Inc. | Méthodes de traitement d'une tauopathie |
JP6629201B2 (ja) * | 2013-11-27 | 2020-01-15 | アイピエリアン,インコーポレイティド | タウオパチーの処置方法 |
MX2017004975A (es) * | 2014-10-18 | 2017-06-30 | Pfizer | Composiciones de anticuerpos anti-il-7r. |
-
2017
- 2017-06-16 JP JP2019569225A patent/JP2020529394A/ja active Pending
- 2017-06-16 EP EP17743107.9A patent/EP3638694A1/fr not_active Withdrawn
- 2017-06-16 AU AU2017418317A patent/AU2017418317A1/en not_active Abandoned
- 2017-06-16 CN CN201780091913.0A patent/CN110770253A/zh active Pending
- 2017-06-16 CA CA3064550A patent/CA3064550A1/fr active Pending
- 2017-06-16 BR BR112019026298-9A patent/BR112019026298A2/pt unknown
- 2017-06-16 WO PCT/US2017/037991 patent/WO2018231254A1/fr active Application Filing
- 2017-06-16 KR KR1020197038545A patent/KR20200018502A/ko not_active Application Discontinuation
- 2017-06-16 EA EA202090063A patent/EA202090063A1/ru unknown
- 2017-06-16 MX MX2019015071A patent/MX2019015071A/es unknown
-
2019
- 2019-12-08 IL IL271256A patent/IL271256A/en unknown
-
2021
- 2021-11-10 JP JP2021182954A patent/JP2022033757A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2017418317A1 (en) | 2019-12-05 |
WO2018231254A1 (fr) | 2018-12-20 |
IL271256A (en) | 2020-01-30 |
EA202090063A1 (ru) | 2020-04-03 |
JP2020529394A (ja) | 2020-10-08 |
BR112019026298A2 (pt) | 2020-07-14 |
EP3638694A1 (fr) | 2020-04-22 |
KR20200018502A (ko) | 2020-02-19 |
CN110770253A (zh) | 2020-02-07 |
JP2022033757A (ja) | 2022-03-02 |
MX2019015071A (es) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3064550A1 (fr) | Compositions et methodes de traitement de tauopathies | |
US20220411486A1 (en) | Humanized Antibodies That Recognize Alpha-Synuclein | |
US10808027B2 (en) | DNA molecules encoding antibodies to tau and methods of making thereof | |
US20070148168A1 (en) | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | |
US20200377579A1 (en) | Compositions and methods for treating synucleinopathies | |
EA036014B1 (ru) | Антитела к транстиретину | |
JP7045327B2 (ja) | 抗血液樹状細胞抗原2抗体の臨床使用のための医薬組成物及び投与レジメン | |
KR20180081522A (ko) | 신경계 및 다른 장애의 치료를 위한 결합 효능제 | |
US11702467B2 (en) | High affinity antibodies targeting tau phosphorylated at serine 413 | |
US20190135905A1 (en) | Compositions and methods for treating tauopathies | |
NZ789385A (en) | Compositions and methods for treating tauopathies | |
AU2013231110A1 (en) | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220614 |
|
EEER | Examination request |
Effective date: 20220614 |
|
EEER | Examination request |
Effective date: 20220614 |
|
EEER | Examination request |
Effective date: 20220614 |